Immune system disorder
MONDO:0005046A disorder resulting from an abnormality in the immune system.
Also known as: disease of immune system, disease or disorder of immune system, disorder of immune system, immune disease, immune disorder, immune dysfunction, immune system disease or disorder, immune system disorder
12993 clinical trials for this condition and its sub-types, 152 tagged with Immune system disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Immune system disorder
-
Autoimmune disease 315 trials · 4,049 incl. sub-types
47 sub-types
- Autoimmune disorder of the nervous system 47 trials · 1,067 incl. sub-types Sub-types →
- Autoimmune disorder of gastrointestinal tract 0 trials · 942 incl. sub-types Sub-types →
- Autoimmune disorder of endocrine system 1 trial · 929 incl. sub-types Sub-types →
- CNS demyelinating autoimmune disease 5 trials · 859 incl. sub-types Sub-types →
- Autoimmune disorder of musculoskeletal system 0 trials · 797 incl. sub-types Sub-types →
- Lupus erythematosus 40 trials · 551 incl. sub-types Sub-types →
- Scleroderma 47 trials · 305 incl. sub-types Sub-types →
- Autoimmune disorder of exocrine system 0 trials · 197 incl. sub-types Sub-types →
- Autoimmune disorder of blood 0 trials · 152 incl. sub-types Sub-types →
- Autoimmune thrombocytopenia 8 trials · 113 incl. sub-types Sub-types →
- Vitiligo 100 trials Sub-types →
- Antiphospholipid syndrome 58 trials · 59 incl. sub-types Sub-types →
- Autoimmune bullous skin disease 7 trials · 56 incl. sub-types Sub-types →
- Immunoglobulin G4-related sclerosing disease 30 trials · 34 incl. sub-types Sub-types →
- Rheumatic fever 17 trials
- Overlapping connective tissue disease 2 trials · 15 incl. sub-types Sub-types →
- Autoimmune lymphoproliferative syndrome 11 trials · 12 incl. sub-types Sub-types →
- Undifferentiated connective tissue syndrome 7 trials
- Autoimmune pulmonary alveolar proteinosis 6 trials
- Type III hypersensitivity disease 3 trials · 6 incl. sub-types Sub-types →
- Anti-glomerular basement membrane disease 5 trials
- Autoimmune disease of ear, nose and throat 0 trials · 4 incl. sub-types Sub-types →
- Autoimmune disorder of cardiovascular system 0 trials · 3 incl. sub-types Sub-types →
- Cryoglobulinemia 3 trials Sub-types →
- Susac syndrome 2 trials
- Autoimmune disease, multisystem, infantile-onset 0 trials · 2 incl. sub-types Sub-types →
- Anti-neutrophil antibody associated vasculitis 1 trial
- Phacolytic glaucoma 1 trial
- Secondary neonatal autoimmune disease 0 trials · 1 incl. sub-types Sub-types →
- Jaccoud syndrome 0 trials
- Kimura disease 0 trials
- Reynolds syndrome 0 trials
- Autoerythrocyte sensitization syndrome 0 trials
- Autoimmune disease with susceptibility to mycobacterium tuberculosis 0 trials
- Autoimmune glomerulonephritis 0 trials
- Autoimmune pulmonary disease due to PD-1 deficiency 0 trials
- Autoimmune urticaria 0 trials
- Euthyroid Graves orbitopathy 0 trials
- Multisystem autoimmune disease due to IKAROS gain of function 0 trials
- Non-specific autoimmune brainstem encephalitis with characteristic antibodies 0 trials
- Non-specific autoimmune brainstem encephalitis without characteristic antibodies 0 trials
- Non-specific autoimmune cerebellar ataxia with characteristic antibodies 0 trials
- Non-specific autoimmune cerebellar ataxia without characteristic antibodies 0 trials
- Non-specific autoimmune supratentorial encephalitis with characteristic antibodies 0 trials
- Non-specific autoimmune supratentorial encephalitis without characteristic antibodies 0 trials
- Tempi syndrome 0 trials
- Type II hypersensitivity reaction disease 0 trials
-
Leukocyte disorder 6 trials · 3,581 incl. sub-types
23 sub-types
- B-cell neoplasm 305 trials · 3,174 incl. sub-types Sub-types →
- T-cell leukemia 9 trials · 137 incl. sub-types Sub-types →
- B cell deficiency 5 trials · 86 incl. sub-types Sub-types →
- Leukopenia 6 trials · 78 incl. sub-types Sub-types →
- Dendritic cell sarcoma 0 trials · 53 incl. sub-types Sub-types →
- Eosinophil disorder 2 trials · 51 incl. sub-types Sub-types →
- Langerhans cell histiocytosis 40 trials · 41 incl. sub-types Sub-types →
- Phagocyte bactericidal dysfunction 0 trials · 37 incl. sub-types Sub-types →
- Mastocytosis 15 trials · 34 incl. sub-types Sub-types →
- Functional neutrophil defect 0 trials · 13 incl. sub-types Sub-types →
- Mast cell activation syndrome 8 trials · 9 incl. sub-types Sub-types →
- POEMS syndrome 8 trials
- Subcutaneous panniculitis-like T-cell lymphoma 8 trials
- EBV-positive T-cell lymphoproliferative disorder of childhood 3 trials · 7 incl. sub-types Sub-types →
- Thymoma type B 0 trials · 4 incl. sub-types Sub-types →
- Human granulocytic anaplasmosis 1 trial
- Pelger-Huet anomaly 0 trials
- Eosinophil peroxidase deficiency 0 trials
- Hereditary neutrophilia 0 trials
- Human monocytic ehrlichiosis 0 trials
- Leukostasis 0 trials
- Pituitary gland basophil adenoma 0 trials
- Small intestinal enteropathy-associated T-cell lymphoma 0 trials
-
Immune system cancer 0 trials · 3,127 incl. sub-types
25 sub-types
- Bone marrow cancer 2 trials · 1,633 incl. sub-types Sub-types →
- Plasma cell myeloma 1,108 trials · 1,131 incl. sub-types Sub-types →
- Thymus cancer 10 trials · 225 incl. sub-types Sub-types →
- Primary central nervous system lymphoma 92 trials · 103 incl. sub-types Sub-types →
- Lymphatic system cancer 4 trials · 70 incl. sub-types Sub-types →
- Dendritic cell sarcoma 0 trials · 53 incl. sub-types Sub-types →
- B-cell childhood acute lymphoblastic leukemia 37 trials
- T-cell childhood acute lymphocytic leukemia 10 trials
- Waldeyer's ring cancer 0 trials · 8 incl. sub-types Sub-types →
- Subcutaneous panniculitis-like T-cell lymphoma 8 trials
- Primary vitreoretinal large b-cell lymphoma 3 trials
- Indolent primary cutaneous B-cell lymphoma 1 trial · 2 incl. sub-types Sub-types →
- Systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood 2 trials
- Breast diffuse large B-cell lymphoma 1 trial
- Colon Burkitt lymphoma 0 trials
- Colorectal diffuse large B-cell lymphoma 0 trials
- Gastric mantle cell lymphoma 0 trials
- Liver diffuse large B-cell lymphoma 0 trials
- Mast cell sarcoma 0 trials
- Primary pulmonary diffuse large B-cell lymphoma 0 trials
- Small intestinal Burkitt lymphoma 0 trials
- Small intestinal diffuse large B-cell lymphoma 0 trials
- Small intestinal enteropathy-associated T-cell lymphoma 0 trials
- Solitary plasmacytoma of chest wall 0 trials
- Thyroid gland diffuse large B-cell lymphoma 0 trials
-
Bone marrow disorder 18 trials · 1,763 incl. sub-types
7 sub-types
- Bone marrow neoplasm 3 trials · 1,633 incl. sub-types Sub-types →
- Polycythemia 9 trials · 99 incl. sub-types Sub-types →
- Bone marrow failure syndrome 48 trials Sub-types →
- Osteomyelitis 43 trials · 46 incl. sub-types Sub-types →
- Fanconi anemia 29 trials · 42 incl. sub-types Sub-types →
- Drachtman Weinblatt Sitarz syndrome 0 trials
- Premature ovarian failure 15 0 trials
-
Inflammatory bowel disease 430 trials · 1,081 incl. sub-types
40 sub-types
- Colitis 41 trials · 679 incl. sub-types Sub-types →
- Crohn disease 563 trials · 569 incl. sub-types Sub-types →
- Proctitis 2 trials · 21 incl. sub-types Sub-types →
- Inflammatory bowel disease 1 3 trials
- Undetermined colitis 3 trials
- Ulcerative proctosigmoiditis 2 trials
- ALPI-related inflammatory bowel disease 0 trials
- IL10-related early-onset inflammatory bowel disease 0 trials Sub-types →
- TRIM22-related inflammatory bowel disease 0 trials
- Cap polyposis 0 trials
- Cutaneous photosensitivity-lethal colitis syndrome 0 trials
- Inflammatory bowel disease (infantile ulcerative colitis) 31, autosomal recessive 0 trials
- Inflammatory bowel disease 10 0 trials
- Inflammatory bowel disease 11 0 trials
- Inflammatory bowel disease 12 0 trials
- Inflammatory bowel disease 13 0 trials
- Inflammatory bowel disease 14 0 trials
- Inflammatory bowel disease 15 0 trials
- Inflammatory bowel disease 16 0 trials
- Inflammatory bowel disease 17 0 trials
- Inflammatory bowel disease 18 0 trials
- Inflammatory bowel disease 19 0 trials
- Inflammatory bowel disease 2 0 trials
- Inflammatory bowel disease 20 0 trials
- Inflammatory bowel disease 21 0 trials
- Inflammatory bowel disease 22 0 trials
- Inflammatory bowel disease 23 0 trials
- Inflammatory bowel disease 24 0 trials
- Inflammatory bowel disease 26 0 trials
- Inflammatory bowel disease 27 0 trials
- Inflammatory bowel disease 29 0 trials
- Inflammatory bowel disease 3 0 trials
- Inflammatory bowel disease 30 0 trials
- Inflammatory bowel disease 4 0 trials
- Inflammatory bowel disease 5 0 trials
- Inflammatory bowel disease 6 0 trials
- Inflammatory bowel disease 7 0 trials
- Inflammatory bowel disease 8 0 trials
- Inflammatory bowel disease 9 0 trials
- Neonatal inflammatory skin and bowel disease 0 trials Sub-types →
-
Hypersensitivity reaction disease 32 trials · 1,025 incl. sub-types
10 sub-types
- Allergic disease 179 trials · 969 incl. sub-types Sub-types →
- Anaphylaxis 26 trials · 27 incl. sub-types Sub-types →
- Type IV hypersensitivity disease 0 trials · 18 incl. sub-types Sub-types →
- Hypersensitivity vasculitis 0 trials · 16 incl. sub-types Sub-types →
- Immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome 10 trials
- IgE responsiveness, atopic 9 trials
- Type III hypersensitivity disease 3 trials · 6 incl. sub-types Sub-types →
- Progestogen hypersensitivity 3 trials
- Pseudoallergy 0 trials Sub-types →
- Type II hypersensitivity reaction disease 0 trials
-
Immunodeficiency disease 55 trials · 779 incl. sub-types
95 sub-types
- T-cell immunodeficiency 4 trials · 484 incl. sub-types Sub-types →
- B cell deficiency 5 trials · 86 incl. sub-types Sub-types →
- Myalgic encephalomeyelitis/chronic fatigue syndrome 75 trials
- Combined immunodeficiency 3 trials · 57 incl. sub-types Sub-types →
- Complement deficiency 2 trials · 28 incl. sub-types Sub-types →
- X-linked lymphoproliferative syndrome 7 trials · 11 incl. sub-types Sub-types →
- GATA2 deficiency with susceptibility to MDS/AML 5 trials · 8 incl. sub-types Sub-types →
- Idiopathic CD4 lymphocytopenia 7 trials
- IKBKG-related immunodeficiency with or without ectodermal dysplasia 0 trials · 4 incl. sub-types Sub-types →
- Immunodeficiency due to selective anti-polysaccharide antibody deficiency 2 trials
- IRF4-related immune disorder 1 trial Sub-types →
- PTEN harmartoma tumor syndrome with immune disorder 1 trial
- Immunodeficiency 23 1 trial
- Immunodeficiency 31B 1 trial
- DNAJC21-related Shwachman Diamond syndrome 0 trials
- DOCK2 deficiency 0 trials
- FADD-related immunodeficiency 0 trials
- FASLG-related immunodeficiency 0 trials
- FNIP1-associated syndrome 0 trials
- Shwachman-Diamond syndrome 1 0 trials
- TFRC-related combined immunodeficiency 0 trials
- TNFRSF9-related immunodeficiency 0 trials Sub-types →
- Wiskott-Aldrich syndrome 2 0 trials
- Wiskott-Aldrich syndrome, autosomal dominant form 0 trials
- Autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome 0 trials
- Chronic mucocutaneous candidiasis and connective tissue disease due to JNK1 haploinsufficiency 0 trials
- Cryptosporidiosis-chronic cholangitis-liver disease syndrome 0 trials
- Hatipoglu immunodeficiency syndrome 0 trials
- Hypoproteinemia, hypercatabolic 0 trials
- Immune deficiency due to impaired neutrophil phagocytosis and migration 0 trials
- Immunodeficiency 101 (varicella zoster virus-specific) 0 trials
- Immunodeficiency 102 0 trials
- Immunodeficiency 106, susceptibility to viral infections 0 trials
- Immunodeficiency 107, susceptibility to invasive staphylococcus aureus infection 0 trials
- Immunodeficiency 112 0 trials
- Immunodeficiency 113 with autoimmunity and autoinflammation 0 trials
- Immunodeficiency 114, folate-responsive 0 trials
- Immunodeficiency 115 with autoinflammation 0 trials
- Immunodeficiency 117 0 trials
- Immunodeficiency 118 0 trials
- Immunodeficiency 119 0 trials
- Immunodeficiency 11b with atopic dermatitis 0 trials
- Immunodeficiency 121 with autoinflammation 0 trials
- Immunodeficiency 122 0 trials
- Immunodeficiency 123 with HPV-related verrucosis 0 trials
- Immunodeficiency 125 0 trials
- Immunodeficiency 126, susceptibility to 0 trials
- Immunodeficiency 127 0 trials
- Immunodeficiency 128 0 trials
- Immunodeficiency 132b 0 trials
- Immunodeficiency 133 with ectodermal dysplasia with or without peripheral neuropathy 0 trials
- Immunodeficiency 134 (Epstein-Barr virus-specific) 0 trials
- Immunodeficiency 14b, autosomal recessive 0 trials
- Immunodeficiency 15a 0 trials
- Immunodeficiency 35 0 trials
- Immunodeficiency 45 0 trials
- Immunodeficiency 53 0 trials
- Immunodeficiency 57 0 trials
- Immunodeficiency 60 0 trials
- Immunodeficiency 62 0 trials
- Immunodeficiency 63 with lymphoproliferation and autoimmunity 0 trials
- Immunodeficiency 64 0 trials
- Immunodeficiency 65, susceptibility to viral infections 0 trials
- Immunodeficiency 66 0 trials
- Immunodeficiency 67 0 trials
- Immunodeficiency 69 0 trials
- Immunodeficiency 70 0 trials
- Immunodeficiency 72 with autoinflammation 0 trials
- Immunodeficiency 74, COVID-19-related, X-linked 0 trials
- Immunodeficiency 75 0 trials
- Immunodeficiency 76 0 trials
- Immunodeficiency 77 0 trials
- Immunodeficiency 78 with autoimmunity and developmental delay 0 trials
- Immunodeficiency 80 with or without congenital cardiomyopathy 0 trials
- Immunodeficiency 81 0 trials
- Immunodeficiency 82 with systemic inflammation 0 trials
- Immunodeficiency 84 0 trials
- Immunodeficiency 85 and autoimmunity 0 trials
- Immunodeficiency 86 0 trials
- Immunodeficiency 87 and autoimmunity 0 trials
- Immunodeficiency 88 0 trials
- Immunodeficiency 89 and autoimmunity 0 trials
- Immunodeficiency 91 and hyperinflammation 0 trials
- Immunodeficiency 92 0 trials
- Immunodeficiency 93 and hypertrophic cardiomyopathy 0 trials
- Immunodeficiency 95 0 trials
- Immunodeficiency 96 0 trials
- Immunodeficiency 97 with autoinflammation 0 trials
- Immunodeficiency 98 with autoinflammation, X-linked 0 trials
- Immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias 0 trials
- Immunodeficiency due to CD25 deficiency 0 trials
- Lymphoproliferative syndrome 1 0 trials
- Primary immunodeficiency due to calcium channel deficiency 0 trials
- Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency 0 trials
- Pyogenic bacterial infections due to MyD88 deficiency 0 trials
-
Lymphoid system disorder 1 trial · 749 incl. sub-types
5 sub-types
- Lymphatic system disorder 31 trials · 711 incl. sub-types Sub-types →
- Tonsillitis 23 trials · 28 incl. sub-types Sub-types →
- Waldeyer's ring cancer 0 trials · 8 incl. sub-types Sub-types →
- Tonsil neoplasm 0 trials · 8 incl. sub-types Sub-types →
- Peritonsillar abscess 4 trials
-
Psoriasis 381 trials
3 sub-types
- Pustular psoriasis 6 trials · 39 incl. sub-types Sub-types →
- Guttate psoriasis 2 trials
- Psoriasis 2 0 trials
-
Inborn error of immunity 121 trials · 345 incl. sub-types
40 sub-types
- Lymphoproliferative syndrome 70 trials · 100 incl. sub-types Sub-types →
- B cell deficiency 5 trials · 86 incl. sub-types Sub-types →
- Phagocyte bactericidal dysfunction 0 trials · 37 incl. sub-types Sub-types →
- Complement deficiency 2 trials · 28 incl. sub-types Sub-types →
- Hereditary hemophagocytic lymphohistiocytosis 8 trials · 16 incl. sub-types Sub-types →
- Aicardi-Goutieres syndrome 9 trials Sub-types →
- Familial isolated congenital asplenia 6 trials
- Chronic mucocutaneous candidiasis 4 trials Sub-types →
- Immunoglobulin heavy chain deficiency 0 trials · 2 incl. sub-types Sub-types →
- A20 haploinsufficiency 1 trial
- BENTA disease 1 trial
- Immuno-osseous dysplasia 0 trials · 1 incl. sub-types Sub-types →
- Immunodysregulation with variable immunodeficiency and autoimmunity 1 trial
- IL10-related early-onset inflammatory bowel disease 0 trials Sub-types →
- NK cell deficiency 0 trials
- Say-Barber-Miller syndrome 0 trials
- T cell and NK cell immunodeficiency 0 trials
- T-cell immunodeficiency with epidermodysplasia verruciformis 0 trials
- X-linked immunoneurologic disorder 0 trials
- Autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicity 0 trials
- Combined immunodeficiency due to moesin deficiency 0 trials
- Combined immunodeficiency with faciooculoskeletal anomalies 0 trials
- Dendritic cell deficiency 0 trials
- Ectodermal dysplasia and immune deficiency 0 trials Sub-types →
- Hepatic veno-occlusive disease-immunodeficiency syndrome 0 trials
- Immune dysregulation with immunodeficiency due to AIOLOS haploinsufficiency 0 trials
- Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome 0 trials
- Immunodeficiency 28 0 trials
- Immunodeficiency 33 0 trials
- Immunodeficiency 37 0 trials Sub-types →
- Immunodeficiency 39 0 trials
- Immunodeficiency 47 0 trials
- Immunodeficiency 49 0 trials
- Immunodeficiency with defective T-cell response to interleukin 1 0 trials
- Immunodeficiency, X-linked, with deficiency of 115,000 Dalton surface glycoprotein 0 trials
- Inflammatory bowel disease-recurrent sinopulmonary infections syndrome 0 trials
- Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection 0 trials
- Properdin deficiency, X-linked 0 trials
- Recurrent infections associated with rare immunoglobulin isotypes deficiency 0 trials
- Trichohepatoenteric syndrome 0 trials Sub-types →
-
Graft versus host disease 186 trials · 300 incl. sub-types
2 sub-types
- Chronic graft versus host disease 118 trials
- Acute graft versus host disease 86 trials
-
Thymus gland disorder 1 trial · 240 incl. sub-types
3 sub-types
- Thymus neoplasm 5 trials · 240 incl. sub-types Sub-types →
- Ectopic thymus 0 trials
- Thymic dysplasia 0 trials
-
Spondyloarthropathy 122 trials · 199 incl. sub-types
3 sub-types
- Ankylosing spondylitis 110 trials · 114 incl. sub-types Sub-types →
- Kummell disease 1 trial
- Hypermobility of coccyx 0 trials
-
Thrombocytopenic purpura 8 trials · 116 incl. sub-types
2 sub-types
- Autoimmune thrombocytopenic purpura 95 trials
- Thrombotic thrombocytopenic purpura 15 trials · 20 incl. sub-types Sub-types →
-
Granulomatosis with polyangiitis 95 trials · 115 incl. sub-types
1 sub-type
-
Phagocytic cell dysfunction 1 trial · 77 incl. sub-types
7 sub-types
- Langerhans cell histiocytosis 40 trials · 41 incl. sub-types Sub-types →
- Defective phagocytic cell engulfment 0 trials · 37 incl. sub-types Sub-types →
- Phagocyte bactericidal dysfunction 0 trials · 37 incl. sub-types Sub-types →
- Defective phagocytic cell chemotaxis 0 trials
- Defective phagocytic cell opsonization 0 trials
- Familial lipochrome histiocytosis 0 trials
- Phagocytosis, plasma-related defect 1N 0 trials
-
Cytokine release syndrome 33 trials
-
Immunoproliferative disorder 19 trials
-
Familial Mediterranean fever 15 trials
2 sub-types
-
Immunodeficiency-related disorder 1 trial · 15 incl. sub-types
1 sub-type
- AIDS-related disorder 3 trials · 14 incl. sub-types Sub-types →
-
Twin to twin transfusion syndrome 14 trials
1 sub-type
-
22q11.2 deletion syndrome 7 trials · 13 incl. sub-types
4 sub-types
- DiGeorge syndrome 11 trials
- Velocardiofacial syndrome 4 trials
- Chromosome 22q11.2 deletion syndrome, distal 0 trials
- Congenital unilateral hypoplasia of depressor anguli oris 0 trials
-
Cryopyrin-associated periodic syndrome 10 trials
3 sub-types
- CINCA syndrome 4 trials
- Muckle-Wells syndrome 3 trials
- Familial cold autoinflammatory syndrome 3 trials Sub-types →
-
Acquired immunodeficiency 5 trials
2 sub-types
- Good syndrome 0 trials
- Acquired adult-onset immunodeficiency 0 trials
-
Anti-HLA hyperimmunization 3 trials
-
6 sub-types
- Proteasome-associated autoinflammatory syndrome 1 1 trial
- Proteasome-associated autoinflammatory syndrome 2 0 trials
- Proteasome-associated autoinflammatory syndrome 3 0 trials
- Proteasome-associated autoinflammatory syndrome 4 0 trials
- Proteasome-associated autoinflammatory syndrome 5 0 trials
- Proteasome-associated autoinflammatory syndrome 6 0 trials
-
Roifman syndrome 1 trial
-
Aggressive insulitis 1 trial
-
Transcobalamin II deficiency 1 trial
-
CADINS disease 0 trials
-
Vici syndrome 0 trials
-
Autosomal recessive osteopetrosis 7 0 trials
-
Benign insulitis 0 trials
-
Cytokine receptor deficiency 0 trials
-
Epidermodysplasia verruciformis 0 trials
1 sub-type
-
Erythroderma desquamativum 0 trials
-
Immune system organ benign neoplasm 0 trials
3 sub-types
- Benign neoplasm of lymph node 0 trials
- Benign neoplasm of spleen 0 trials Sub-types →
- Benign neoplasm of thymus 0 trials Sub-types →
Most studied deeper sub-types
-
MRNA HIV vaccine trial launches in healthy volunteers
Vaccine OngoingThis early-stage trial tests whether three experimental mRNA vaccines can safely teach the immune system to recognize and fight HIV. About 108 healthy, HIV-negative adults aged 18-55 will receive one of the vaccines. The main goal is to check for side effects and see if the vacci…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Jun 27, 2026 07:54 UTC
-
New CAR T-Cell therapy targets Hard-to-Treat multiple myeloma
Disease control OngoingThis early-phase study tests a new treatment for multiple myeloma that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells (T cells) that are modified in the lab to recognize and attack cancer cells carrying a protein called CD138. …
Phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill could tame lupus flares in major trial
Disease control OngoingThis phase 3 trial tests whether adding cenerimod, a daily pill, to standard lupus treatments can reduce symptoms in adults with moderate-to-severe systemic lupus erythematosus (SLE). About 470 participants will receive either cenerimod or a placebo for 12 months. Researchers wil…
Phase 3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New lupus pill shows promise in major trial
Disease control OngoingThis Phase 3 study tests whether adding cenerimod to standard lupus treatments can better control moderate-to-severe lupus symptoms. About 451 adults will receive either cenerimod or a placebo for 12 months. The main goal is to see if more people improve on a lupus disease activi…
Phase 3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New stem cell transplant trial aims to control tough lymphoma
Disease control OngoingThis study tests a stem cell transplant to control peripheral T-cell lymphoma in people whose cancer has not responded to standard treatments. Participants receive a donor's stem cells after chemotherapy or antibody therapy to prepare their body. The goal is to see if this approa…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New lupus drug tested for Long-Term safety in 680 patients
Disease control By invitation onlyThis study looks at the long-term safety of cenerimod in adults with moderate-to-severe lupus. About 680 participants who were in a previous study will take cenerimod for up to 3 years, along with their usual lupus medications. Researchers will track side effects and see how well…
Phase 3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New lupus drug shows promise in Long-Term safety trial
Disease control By invitation onlyThis study looks at the long-term safety of a drug called litifilimab for people with active lupus. About 864 adults who finished earlier studies will continue taking the drug for up to 3 years, along with their usual treatments. The goal is to see how safe it is and how well it …
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug aims to tame scleroderma in major trial
Disease control OngoingThis Phase 3 study tests whether anifrolumab, given as a weekly shot, can improve symptoms of systemic sclerosis (scleroderma) compared to a placebo. About 314 adults aged 18-70 with early-stage disease will take part. The main goal is to see if more people respond to treatment, …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Lower drug dose after transplant may cut infections without losing protection
Disease control OngoingThis study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease (a common complication where donor cells att…
Phase 2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New lupus drug afimetoran enters Mid-Stage trial
Disease control OngoingThis phase 2 trial tests whether the drug afimetoran can safely control active systemic lupus erythematosus (SLE) better than a placebo. About 268 participants with lupus will receive either afimetoran or a placebo for 48 weeks, with an extension period allowing placebo users to …
Phase 2 • Sponsor: Beeline Medicines Corporation • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can calming the immune system save Kids' livers?
Disease control OngoingThis study tests whether two drugs that calm the immune system—high-dose steroids or anti-thymocyte globulin—can help children with sudden, severe liver failure survive without needing a liver transplant. About 163 children aged 1 to 17 will be randomly assigned to receive one of…
Phase 2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Engineered immune cells with an emergency brake tested in lymphoma
Disease control OngoingThis early-phase study tests a new type of CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. The cells are engineered to target and kill cancer cells, but also include a safety switch that can be activated to reduce severe side e…
Phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a new drug safely control eczema over the long haul?
Disease control By invitation onlyThis trial is investigating whether long-term use of an experimental drug called IMG-007 can safely control moderate-to-severe eczema (atopic dermatitis). The study enrolls people who have already completed a previous IMG-007 trial and will receive the drug as a shot under the sk…
Phase 2 • Sponsor: Inmagene LLC • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New lupus pill shows promise in Mid-Stage trial
Disease control OngoingThis Phase 2 study tests an experimental oral drug called ESK-001 in 408 adults with active systemic lupus erythematosus (SLE). Participants receive either ESK-001 or a placebo for 48 weeks to see if the drug can reduce disease activity. The goal is to find a new treatment option…
Phase 2 • Sponsor: Alumis Inc • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New antibody drug aims to halt Scleroderma's damage
Disease control OngoingThis Phase 2 trial tests a drug called tibulizumab in 80 adults with systemic sclerosis, a disease that causes skin thickening and can damage organs. Participants first receive either the drug or a placebo for 24 weeks, then everyone who continues gets the drug for another 28 wee…
Phase 2 • Sponsor: Zura Bio Inc • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Supercharged immune cells take on tough lymphomas
Disease control OngoingThis study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard therapy. The treatment involves taking a patient's own T cells (a type of immune cell), adding a gene that helps them recognize and attack lymphoma cell…
Phase 1/2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Engineered immune cells with 'Off Switch' tested for tough leukemia
Disease control OngoingThis early-phase trial tests a new type of CAR-T cell therapy for people with relapsed or hard-to-treat acute lymphoblastic leukemia. The cells are engineered to recognize and kill leukemia cells, but also include a safety switch that can be turned on to calm them down if side ef…
Phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Engineered immune cells take aim at tough lymphomas in first human test
Disease control OngoingThis early-phase trial tests a new type of immunotherapy for people with Hodgkin lymphoma or cutaneous T-cell lymphoma that has returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are genetically modified to recognize and attack can…
Phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis study tests a daily oral drug called nemtabrutinib (ARQ 531) in 190 people with blood cancers like lymphoma or leukemia that have come back or not responded to prior treatment. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-phase trial,…
Phase 1/2 • Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Supercharged immune cells aim to stop lymphoma comeback
Disease control OngoingThis early-phase trial tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma who have had a stem cell transplant. The treatment uses the patient's own T cells, which are modified in a lab to recognize and attack cancer cells that carry a protein called CD30. The m…
Phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Can magnetic waves tame autoimmune disease? new trial begins
Disease control By invitation onlyThis study tests a non-invasive device that uses low-frequency electromagnetic fields to improve communication between immune cells. 120 adults with lupus, rheumatoid arthritis, or multiple sclerosis will receive either active or sham sessions three times a week for 12 weeks. The…
Phase 1/2 • Sponsor: Truway Health, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Peer support could boost HIV med adherence and curb substance use
Disease control OngoingThis study tests a program called Khanya, where trained peers (people with lived substance use experience) help HIV patients stick to their medication and reduce drug or alcohol use. The program is offered in steps: a basic version first, then a more intensive one if needed. Rese…
Sponsor: University of Maryland, College Park • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Can a new immune system fix T-Cell diseases? trial tests donor transplants
Disease control OngoingThis study tests whether a stem cell transplant from a healthy donor can safely treat people with severe T-cell problems. Participants receive chemotherapy and antibody therapy before the transplant, followed by donor stem cells. The goal is to see if the new immune system can co…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New shot could tame Sjögren's Flare-Ups
Disease control OngoingThis Phase 2 trial tests whether sibeprenlimab, a biologic drug given as a shot every 4 weeks, can reduce disease activity and symptoms in people with Sjögren's disease. About 83 adults with moderate-to-active disease will receive either the drug or a placebo, added to their usua…
Phase 2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for blood cancer patients: using mismatched donors for transplants
Disease control OngoingThis study tests a stem cell transplant using donors who are not a perfect match for patients with blood cancers like leukemia and lymphoma. Doctors give special drugs after the transplant to help prevent the donor cells from attacking the patient's body. The goal is to see if th…
Phase 2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Milder stem cell transplant shows promise for kids with immune disorders
Disease control OngoingThis study tests a stem cell transplant using a milder chemotherapy-like regimen to treat children and young adults (up to age 28) with various immune system disorders. The goal is to help the donor stem cells settle in the body with fewer side effects. The study involves 20 part…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug could slow kidney failure in IgA nephropathy patients
Disease control OngoingThis study tests a drug called telitacicept in 318 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants are at high risk of worsening despite standard blood pressure medications. The goal is to see if telitacicept can reduce protein in the u…
Phase 3 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New lupus pill shows promise in major trial
Disease control OngoingThis study tests whether the drug deucravacitinib can safely control symptoms in people with active moderate-to-severe lupus. About 513 participants will receive either the drug or a placebo. The goal is to see if the drug reduces lupus disease activity better than placebo.
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New pill could tame lupus flares
Disease control OngoingThis Phase 3 trial tests whether the oral drug deucravacitinib can safely control moderate to severe lupus better than a placebo. About 516 adults with active lupus are taking either the drug or a dummy pill for several months. The goal is to see if the drug reduces lupus symptom…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Peanut allergy vaccine? new peptide therapy aims to protect kids
Disease control OngoingThis phase 2 trial tests a new treatment called PVX108 for children and teens with peanut allergy. The treatment uses small pieces of peanut protein to help the immune system become less reactive. About 90 participants will receive either PVX108 or a placebo, and researchers will…
Phase 2 • Sponsor: Aravax Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Gene-Edited stem cells aim to tame HIV
Disease control OngoingThis study tests whether giving HIV patients their own genetically modified stem cells is safe and feasible. The cells are changed to resist HIV, and patients receive a mild chemotherapy drug before infusion. The goal is to see if the modified cells can help control the virus, bu…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Last-Resort treatment opens for rare swallowing disorder
Disease control Expanded access (ended)This program offers APT-1011, a fluticasone tablet that dissolves in the mouth, to patients aged 12 and older with eosinophilic esophagitis who cannot join other studies or have not responded to available treatments. The goal is to provide access until the drug is commercially av…
Sponsor: Ellodi Pharmaceuticals, LP • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Promising ITP drug trial pulled before it even started
Disease control CancelledThis study was designed to test the safety and tolerability of a new drug called HMPL-523 (sovleplenib) in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding problems. The trial was withdrawn before enrolling any pa…
Phase 1 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 26, 2026 18:23 UTC
-
Could a simple injection stop type 1 diabetes before it starts?
Prevention OngoingThis phase II trial tests a drug called Diamyd, given as injections into lymph nodes, to see if it is safe and can prevent type 1 diabetes in children aged 8 to 17 who are at high risk. Only 5 participants are enrolled, and the study focuses on safety and whether the drug can sto…
Phase 2 • Sponsor: Diamyd Medical AB • Aim: Prevention
Last updated Jun 27, 2026 12:10 UTC
-
New drug aims to ease daily misery of rare mast cell disease
Symptom relief OngoingThis phase 2 study tests whether the experimental drug bezuclastinib can reduce symptoms like itching, flushing, and fatigue in people with nonadvanced systemic mastocytosis, a rare condition where too many mast cells cause chronic discomfort. About 237 adults whose symptoms are …
Phase 2 • Sponsor: Cogent Biosciences, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
21,000 lymphoma patients join landmark study to uncover what really affects survival
Knowledge-focused By invitation onlyThis study follows 21,000 adults newly diagnosed with non-Hodgkin lymphoma to learn which factors—like genetics, lifestyle, and treatment—affect survival and quality of life. Researchers will track health outcomes over time without providing a new treatment. The goal is to improv…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Massive study tracks 32,000 oil spill cleanup workers for hidden health risks
Knowledge-focused OngoingThis study follows over 32,000 people who helped clean up the 2010 Deepwater Horizon oil spill in the Gulf of Mexico. Researchers want to see if exposure to crude oil and chemical dispersants leads to long-term health problems like heart disease, cancer, or lung issues. Participa…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Scientists dive into bone marrow to unlock vaccine memory secrets
Knowledge-focused OngoingThis study looks at how the immune system 'remembers' vaccines by tracking special cells in the bone marrow. Twenty-five healthy adults will receive four different vaccines at once and give blood, bone marrow, and lymph node samples over two years. The goal is to understand why s…
Phase 4 • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
New drug SHR-2173 put to the test in healthy volunteers
Knowledge-focused OngoingThis early-stage study is testing a single dose of a new drug called SHR-2173 in 18 healthy adults. The goal is to see how safe it is, how the body absorbs and breaks it down, and whether the immune system reacts to it. Participants will be randomly assigned to receive either the…
Phase 1 • Sponsor: Atridia Pty Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Anesthesia's hidden impact: new study probes immune changes
Knowledge-focused By invitation onlyThis study looks at how three common anesthetics—propofol, sevoflurane, and ciprofol—affect the immune system in 80 healthy adults aged 20-30. Participants are randomly assigned to receive one anesthetic or no anesthesia (control group). Blood samples are taken before, during, an…
Sponsor: Henan Provincial People's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC